Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

Technology Stocks News 17

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported a fourth-quarter 2013 loss of 32 cents per share (excluding one-time expenses), narrower than the year-ago loss of 43 cents per share and the Zacks Consensus Estimate of a loss of 40 cents. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -6.08% in last session and finished the day at $1.70. Traded volume was 1.35million shares in the last session and the average volume of the stock remained 603.66K shares. The beta of the stock remained 0.84. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) insider ownership is 1.50%.

Santander Mexico Financial Group SAB de CV (ADR) (NYSE:BSMX), formerly Grupo Financiero Santander SAB de CV, is a Mexico-based financial institution. The Company is primarily engaged, through its subsidiaries, in the provision of multiple banking services, securities brokerage, financial advice services, as well as other related investment activities. Santander Mexico Fincl Gp SAB deCV (ADR) (NYSE:BSMX) dropped -5.66percent to $10.33 Friday on volume of 1.42million shares. The intra-day range of the stock was $10.30 to $10.60. Santander Mexico Fincl Gp SAB deCV (ADR) (NYSE:BSMX) has a market capitalization of $14.02billion.

Oncothyreon Inc (USA) (NASDAQ:ONTY) had its target price lifted by Stifel Nicolaus from $3.00 to $6.00 in a research note released on Thursday morning. Oncothyreon Inc (USA) (NASDAQ:ONTY)’s stock on Mar 14, 2014 reported a decrease of -5.14% to the closing price of $3.69. Its fifty two weeks range is $1.55 -$4.08. The total market capitalization recorded $255.77million. The overall volume in the last trading session was 1.83million shares. In its share capital, ONTY has 59.96million outstanding shares.

Shares of Omeros Corp (NASDAQ:OMER) , a clinical-stage biopharmaceutical company focused on developing therapies to treat inflammation, coagulopathies, and central nervous system disorders, fell as much as 11% after announcing a share offering of common stock and reporting its fourth-quarter earnings results after the closing bell last night. On Friday, shares of Omeros Corporation (NASDAQ:OMER) dropped -7.72% to close the day at $11.35. Company return on investment (ROI) is -271.30% and its monthly performance is recorded as -4.78%. Omeros Corporation (NASDAQ:OMER) quarterly revenue growth is 57.20%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone